SenzaGen’s Newsletter Q1 2025
Click image to view the Newsletter in browser.
Text-only version:
Scientific highlights from SOT 2025
SOT 2025 in Orlando was a fantastic opportunity to connect with industry leaders and present the latest advancements in GARD® for Skin Sensitization. The strong interest in GARD® was further reinforced by our presentations on its use for Natural Extracts and Medical Devices, as well as its ability to provide quantitative data for safe dose levels and potency GHS/CLP classification. It was great to meet so many of you at SOT, and we look forward to continuing the conversation!
A special thank you to our research partners for their invaluable contributions: dōTERRA | Unilever | Ron Brown | Clarins | Lundbeck | SafeBridge
Advancing NAMs for fragrance safety
A new peer-reviewed study published in ALTEX, conducted in collaboration with RIFM and IFF, confirms the predictive ability of GARD®skin Dose-Response in assessing the skin sensitization potency of fragrance ingredients. The study supports the assay’s application in Quantitative Risk Assessment (QRA) and Next Generation Risk Assessment (NGRA).
With data on 100 fragrance ingredients spanning diverse chemical structures and potency levels, this research represents another step toward more reliable, non-animal testing methods.
Read the new scientific publication
Broadened regulatory testing services
The SenzaGen Group is pleased to announce the implementation of EpiSensA (OECD TG 442D) – making us the first European service provider to offer the new method based on a Reconstructed Human Epidermis (RhE) model.
Talk to one of our experts to learn more
Upcoming events
🌎 Conference: World Congress 13 | Rio de Janeiro, Brazil | Aug 31- Sep 4
🌎 Conference: Eurotox 2025 | Athens, Greece | Sep 14 – 17
